Introduction
The development of retroviral vectors that are targeted to transduce only specific cell types has been the goal of many investigators working in the field of gene therapy [1] [2] [3] [4] [5] . The availability of such vectors would revolutionize the field, opening up new avenues for gene therapy in acquired and inherited disorders by enabling in vivo delivery of therapeutic molecules to specific populations of target cells. Novel approaches to drug delivery and for use in vaccines also become possible, through display of molecules on the retroviral surface.
Over a period of around a decade, however, this goal has proven highly elusive. Virtually all attempts to target specific cell types have logically focused on modification of the retroviral envelope protein, as this complex glycoprotein is established to determine viral host-range and facilitate virus entry though membrane fusion 2, 4, 5 . These modifications can be the simple substitution of the envelope protein for one from another retrovirus, or other enveloped virus, such as vesicular stomatitis virus (VSV) 6 ; a process referred to as pseudotyping 2 . More recently, attempts have been made to deliberately engineer envelope proteins to re-direct their binding to new cell surface molecules 4 . This has involved making N-terminal extensions, insertions or replacements to regions of the envelope protein. Commonly used modifications have been incorporation of growth factor binding regions [7] [8] [9] [10] [11] [12] or the addition of single chain antibodies [13] [14] [15] [16] [17] . Whilst many of these modifications have successfully re-directed viral binding, this has invariably been achieved at the expense of infectivity, to the extent that targeted binding actually inhibited viral entry. This property has actually been utilized to advantage in an approach referred to as "inverse targeting" 10, 18 . A number of reports, however, have indicated that low levels of targeted transduction may be achievable by coexpression of an ecotropic envelope in conjunction with the modified envelope protein 7, 9, 16, 19 .
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To circumvent the problems associated with envelope modification, we have developed an alternative strategy, exploiting the natural budding mechanism of the virus to insert new binding ligands into the viral surface. We describe here successful and efficient, specific targeting of transduction to human cells expressing stem cell factor receptor (c-kit) by ecotropic retroviruses bearing surface stem cell factor.
Materials and Methods
Cytokines antibodies and methylcellulose.
All cytokines used in this study were obtained from First Link (Brierley Hill, W. Mids, UK) and methylcellulose used for clonogenic progenitor assays was obtained from StemCell Technologies (Vancouver, Canada). Mouse anti-human c-kit antibody was obtained from R&D Systems Ltd (Abingdon, Oxford, UK), mouse anti-human CD59 from Serotec (Kidlington, Oxford, UK) and anti-CD34 from BD Bioscience (Cowley, Oxford, UK).
Secondary antibodies, donkey anti-goat IgG, chicken anti-mouse IgG, and rat anti-mouse IgG were purchased from DakoCytomation Ltd. (Ely, Cambs., UK).
Human cell lines.
The human megakaryoblastic leukemia cell line, LAMA-84 20 , the monomyelocytic cell line U937 and the erythroleukemia cell line TF-1 21 were maintained in RPMI supplemented with 10% FCS. TF-1 was supplemented with 1 ng/ml GM-CSF. The human megakaryoblastic leukemia cell line, MO7e 22 , was maintained RPMI supplemented with 20% FCS and 10 ng/ml GM-CSF, or shifted into medium without GM-CSF but containing 100ng/ml SCF for experiments where c-kit expression was down-regulated. Phoenix ecotropic, amphotropic (kind gifts from Dr Gary Nolan, Stanford U) and SCF-eco packaging cell lines were routinely maintained in DMEM supplemented with 10% FCS (Invitrogen-Gibco, Paisley, UK). Retroviral Producer lines were cultured in the same medium supplemented with puromycin (1µg/ml), to select for the PINCO 23 retroviral genome or G418
(1.5 mg/ml) to select for pBabe-neo and pBabe-neo-CDK4 24 . The stable AM-12 retroviral producer cell line previously established in the laboratory by Chinswangwatanakul 24 was maintained in DMEM supplemented with 10% FCS and 1.5 mg/ml G418 for selection of the retroviral vector.
Construction of SCF-eco packaging cells
The membrane-bound form of stem cell factor (mbSCF) cDNA was amplified by RT-PCR from the L88.5 human stromal cell line 25 
Estimation of retroviral titer
The pBabe vectors were titered by G418 resistance as described previously 24 . A similar protocol was followed for CD34+ cells but the transduction cocktail was supplemented with protamine sulfate (4µg/ml), in place of polybrene, and the recombinant human cytokines Flt-3 ligand (100ng/ml), IL-3 (10ng/ml) and GM-CSF (1ng/ml).
Transduction was performed for 96hrs at 37°C in IMDM medium supplemented with 30%
FCS and cells were harvested and assayed as described for cell lines. 5 ), in IMDM supplemented with 30% FCS, protamine sulfate (4µg/ml) and the cytokines, IL-3 (10ng/ml), GM-CSF (1ng/ml) and Flt-3 ligand (100ng/ml) were then transferred to the Transwell™ inserts. Transduction was carried out for 48hrs before the CD34+ cells were harvested and cultured in semi-solid medium, with and without G418 selection, as described below.
CFU-GM assay.
The CD34+ transduced cells were cultured in 3 ml methylcellulose (Methocult H4230, Stem
Cell Technologies, Vancouver, Canada) supplemented with "CFU-GM mix" (50 ng/ml SCF, 1ng/ml GM-CSF, 10ng/ml IL-3 and 100 ng/ml G-CSF) and 1.5 mg/ml G418. After mixing the cells were plated into 35 mm diameter Petri dishes. The cultures were incubated at 37 °C in humidified 5 % CO 2 . CFU-GM colonies of more than 50 cells were scored on day 14 of incubation.
PCR
DNA from transduced MO7e cells was isolated and amplified using primers located in the EGFP sequence. 35 cycles of amplification were performed. The control amplifications were performed on the same samples using primers amplifying a common segment of theinterferon genes. The primer sequences were identified using the software package "Pride"(http://pride.molgen.mpg.de). Primers sequences were as follows: EGFP-F, accccgaccacatgaagcagc; EGFP-R, tcgcctcgaacttcacctc; IFN-F, gaaccagtctagcacatc; IFN-R,
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Day 14, G418-resistant, CFU-GM colonies were plucked directly into a 40 µl PCR mix containing primers specific for the neo resistance gene and PCR carried out using a nested strategy as described in Lewis et al. 24 10µl of the nested products were visualized, as described above.
CFU-GM replating assay (AUC)
Replating assays were performed as described previously 24 . On day 7 of incubation, 90
primary CFU-GM colonies growing in the presence of G418 were plucked with a Gilson P20 pipette and replated individually into 100 µl of methyl cellulose with CFU-GM mix and 1.5 mg/ml G418, in a 96 well, flat-bottom plate (60 wells per plate with the surrounding wells filled with sterile water to prevent evaporation) for secondary colony formation. The replated cultures were allowed to continue growing at 37°C, 5% CO 2 in a humidified incubator, for a further 7 days at which point plates were scored for the presence and number of secondary colonies. The cumulative distribution of secondary CFU-GM colonies was analyzed in a logarithmic plot, relating to log 2 n (the number of doublings required to produce n secondary colonies). The area under the curve (AUC), a parameter providing the kinetics of selfreplication of progenitors was calculated by the trapezium rule.
Results
Retroviruses are now known to acquire many intrinsic host cell membrane proteins as they bud through the plasma membrane [26] [27] [28] [29] . We investigated whether this property could be exploited so that molecules incorporated into the retroviral envelope could be used to redirect binding and transduction of viruses to target cells specifically expressing the appropriate receptor (see Figure 1 ). To this end we constructed an ecotropic retroviral producer cell line expressing the membrane-bound form of human stem cell factor (mbSCF). Using Western blotting, antibody capture of virus and proliferation assays, we established that retroviral particles derived from these modified producers efficiently incorporated mbSCF into the retroviral envelope 30 .
Redirection of retroviral binding
Unlike ecotropic virus, which is only permissive for infection of rodent cells, virus successfully incorporating surface SCF should be capable of binding to human cells that express the SCF receptor, c-kit. We therefore performed virus binding assays to investigate the ability of our SCF-eco viruses to bind to the c-kit-expressing cell line, MO7e 22 . As shown in Figure 2A 
Targeted Transduction of Cell Lines
In contrast with many retroviruses bearing modified envelope proteins, the titer of our SCFeco virus on murine NIH-3T3 cells (2.6 x 10 5 ifu/ml) was found to be comparable to those obtained with unmanipulated ecotropic (eco) or amphotropic (ampho) viruses (3.9x 10 5 and 2.5 x 10 5 ifu/ml, respectively). In all subsequent experiments, volumes of retroviral supernatant were adjusted to equalize the retroviral particle numbers accordingly.
To Figure 4A ). DNA was extracted from the transduced cell populations used in this experiment and subjected to analysis by PCR with virus-specific primers to check for the presence of the retroviral genome (Fig 4B) . Consistent with the transduction data, a positive PCR signal was obtained from cells transduced with ampho or SCF-eco virus but not mock-transduced cells. Although a weaker signal resulted from cells transduced with SCF-eco virus in the presence of growth factor, the conditions used for the PCR make it unlikely that this was due to the reduced efficiency of transduction.
Targeted Transduction of Primary Hematopoietic progenitors
We then investigated the ability of these retroviruses to transduce primary human cells.
Hematopoietic progenitors were obtained from aspirates of normal bone marrow and CD34+ cells isolated by magnetic micro-bead selection (MiniMacs™). The CD34+ populations were tested for representation of c-kit and found to be > 90% positive (Fig 5A) . Transduction of these cells with viral supernatants followed a very similar pattern to that seen previously with the cell lines. Both ampho and SCF-eco virus displayed similar transduction efficiencies, whilst the unmodified ecotropic virus gave virtually no transduction ( Figure 5B ).
We also tested the ability of the different viruses to transduce granulocyte/macrophage colony forming cells (GM-CFC). For this we packaged a different vector, one that encoded a
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From neo gene conferring resistance to the drug G418. Transductions were performed by Transwell™ co-culture 24 ; this allows prolonged exposure to target cells but prevents cell-cell contact. A typical transduction result using bone marrow-derived CD34+ cells is shown in Table 1 and the overall results are summarized in Figure 5C . As observed previously with this transduction system, a high proportion of G418-resistant colonies were obtained with ampho virus 24 . Nevertheless, an equivalent level of transduction was obtained using the SCFeco virus, whereas virtually no G418 resistant colonies resulted from transduction with eco virus. To confirm that the G418 resistant colonies were truly arising from SCF-eco virus transduction of CFU-GM, some of the resistant colonies were analyzed by PCR ( Figure 5D ).
In fifteen out of twenty colonies amplified using primers specific for the neo gene a positive signal was obtained, whilst for the ampho virus twelve out of fourteen colonies tested proved positive. These values are consistent ( 2 test; p= 0.34 and p= 0.72 respectively) with the frequencies of positive scoring colonies (95%) previously observed in validating of this technique 24 . This indicated that retroviral vector genome carried in the SCF-eco retrovirus particles was present in the G418 resistant colonies.
To provide a functional test of our targeting strategy, we took advantage of the fact that the retroviral vector used in these studies also included the cDNA for the cyclin dependent kinase, CDK4. Previous work has shown that expression of this gene in CFU-GM progenitors can increase their frequency of self renewal in a re-plating assay 24 . To evaluate whether the activity of the CDK4 gene could be detected in SCF-eco-transduced colonies, some of these were re-plated and the re-plating efficiency compared with colonies transduced with either the equivalent ampho virus, or an ampho vector containing only the neo resistance marker.
The colony-forming cells transduced by viruses encoding CDK4 did not differ significantly from each other in replating activity (p=0.27), whereas, cells transduced with both ampho In some targeting strategies, retroviral gene delivery in vitro has been found to be particularly dependent on the presence of polycations such as polybrene or lipofectamine during transduction 31 . Although it is not possible to extrapolate this to transduction in vivo 32 , reliance on such agents could compromise the ability of targeted retroviruses to deliver genes in vivo. We therefore tested the ability of our SCF-targeted viruses to deliver the neo gene to CD34+ progenitors in the absence of such agents. Our standard protocols for transduction of CD34+ cells include protamine sulfate. Omission of protamine sulfate from these transductions was found to have no effect on the percentage of GM-colonies resistant to G418 (Fig 5F) , indicating that efficient targeted transduction in our system was not dependent on the presence of polycations.
Discussion
We have described here a novel approach to retroviral targeting that exploits the natural ability of retroviruses to incorporate host cell surface proteins into the lipid envelope of the virus. By producing ecotropic virus from packaging cells that were engineered to express By leaving the retroviral envelope protein intact and separating virus binding from that of fusion, our approach is able to circumvent all these problems. A similar premise has been the basis for studies in which retroviral envelope was substituted by influenza hemagglutinin (HA), to provide a fusion function 35, 36 .
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Regarding the precise mechanism of targeted entry in our system, the role played by the ecotropic envelope protein is of interest. It seems likely that this is providing a fusion function for viral entry, as envelope-free HIV virus like particles (VLP) can be made in abundance but have no infectivity, even though they are able to bind to target cells 37 . It is unclear though, whether the ecotropic receptor is unusual in its apparent ability to fuse independently of binding. One clue may come from the fact that, unlike many other oncoretroviruses, of ecotropic virus entry has been shown in some circumstances to be pHdependent, indicating that rather than interaction at the plasma membrane an endosomal entry route is possible 38 . Late endosomes have a low internal pH, which could be instrumental in triggering the conformational changes required for fusion.
Endocytosis would be advantageous route of entry as late endosomes are primarily perinuclear 39 , this may differ from amphotropic viruses which are pH-independent for entry.
This difference in entry route of targeted and amphotropic viruses might explain the somewhat reduced level of reporter gene expression we observed with targeted transduction.
This may result in lower copy number transductions or perhaps, access to different sites of nuclear integration leading to lower levels of expression.
Targeted vectors in particular would be released from the necessity to perform transductions ex vivo and could herald a new phase of development of gene therapy protocols using in vivo gene delivery. This would be particularly felt in the arena of acquired disease, but also has major ramifications for treating inherited disorders. 
